At ECCO26, ThirtyFiveBio has enabled a team of leading clinicians to meet to evaluate the frontline of gut health. They have published a systematic review in AJP-Gastrointestinal: “Methods for Assessing Intestinal Barrier Function in Patients with IBD.” This systematic review aims to transition IBD care from managing symptoms to the precise measurement and restoration of true mucosal integrity.

The Clinical Challenge: Measuring What Matters

A hallmark of Ulcerative Colitis and Crohn’s disease is the loss of barrier integrity. When the epithelial seal is compromised, it triggers the cascade of inflammation and mucosal damage that physicians see daily in practice. However, to effectively treat the barrier, the community must first be able to measure it with precision.

This systematic review represents a rigorous evaluation of current and emerging technologies used to monitor barrier function. By identifying the most reliable tools, this work helps the clinical community transition from the traditional management of symptoms to the pursuit of true tissue homeostasis resolution.

A Expert-Led Scientific Consensus

This publication is the result of the expertise and dedication of a leading team of clinicians. We would like to specifically recognise Sophie Vieujean and Laurent Peyrin-Biroulet for their expert leadership in establishing this consensus opinion.

Their work addresses a critical gap in IBD care, highlighting the urgent need to make barrier integrity a primary focus for next-generation therapeutic targeting.

Translating Insights into Action: GPR35

While the review establishes the tools for measurement, the next step is providing clinicians with the therapeutic means to intervene.

In alignment with these clinical insights, research is progressing into the role of GPR35, a receptor fundamentally linked to epithelial dysfunction and the loss of mucosal homeostasis. By targeting GPR35, the goal is to provide physicians with a way to move beyond systemic immunosuppression toward:

• Active restoration of the epithelial "shield".
• Promotion of long-term, durable mucosal healing.
• Effective intervention for patients who remain refractory to existing treatments.

We are witnessing a paradigm shift in IBD treatment moving from suppressing the immune system toward the active restoration of the gut's natural defenses.

Access the Full Research

Explore the complete systematic review and the clinical evaluation of current barrier integrity tools here: Read the Publication at American Journal of Physiology -Gastrointestinal

Stay Connected

Whether you engaged with the latest data in Stockholm at ECCO26 or are following our clinical developments from afar, we welcome further dialogue on the GPR35 program and the shared mission to redefine IBD therapy.

Enquiries: enquiries@thirtyfivebio.com Updates: Follow us on LinkedIn

‍